Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
400 participants
OBSERVATIONAL
2008-01-31
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Combination Chemotherapy and Surgical Resection in the Treatment of Adrenocortical Carcinoma: Continuous Infusion Doxorubicin, Vincristine and Etoposide With Daily Mitotane Before and After Surgical Resection
NCT00001339
Dose-finding Study of BP-C1 in Patients With Stage IV Breast Cancer
NCT04298333
Oral Topotecan to Treat Recurrent or Persistent Solid Tumors
NCT00382733
Pharmacokinetic Study on the Addition of Aprepitant to Cisplatin - Etoposide Treatment in Lung Cancer Patients
NCT00588835
Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy
NCT00991094
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Mitotane
Patients with adrenocortical carcinoma treated with mitotane monotherapy
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Treatment with mitotane monotherapy as first-line therapy (in adjuvant setting or advanced disease)
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Wuerzburg
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Martin Fassnacht
Head of Endocrinology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Martin Fassnacht, MD
Role: PRINCIPAL_INVESTIGATOR
University of Wuerzburg
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital
Würzburg, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Wue-ACC-Mitotane
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.